HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Sumatriptan Succinate
SuMitrex · gr43175c · Sumatriptan succinat · Sumatriptan succinate · Succinate Sumatriptan · methanesulfonamide(1:1) · SumatriptanSuccinate>Penehyclidine Impurity 9 · SUMATRIPTANSUCCINATE(1:1)
Identifikatoren & physikalische Daten
| CAS No. | 103628-48-4 |
|---|---|
| Summenformel | C18H27N3O6S |
| Durchschnittliche Molmasse | 413,5 g/mol |
| Monoisotopische Masse | 413,16205676 g/mol |
| SMILES | CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O |
| InChIKey | PORMUFZNYQJOEI-UHFFFAOYSA-N |
| PubChem CID | 59772 |
| ChEMBL | CHEMBL1201150 |
| ChEBI | CHEBI:64359 |
| EC No. | 600-463-4 |
| DTXSID | DTXSID60145966 |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 148 |
|---|---|
| H-Brücken-Donoren | 4 |
| H-Brücken-Akzeptoren | 8 |
| Frei drehbare Bindungen | 9 |
| Schwere Atome | 28 |
| Formalladung | 0 |
| Komplexität | 498 |
| Schmelzpunkt | 165-166°C |
| Lagerbedingungen | -20°C |
| Löslichkeit | H2O: >20mg/mL |
| Aggregatzustand | solid |
| Farbe | white to off-white |
| Merck | 14,8997 |
| BCS Class | 3 |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChI | 1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)35-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H31-2H2,(H,5,6)(H,7,8) |
| InChIKey | PORMUFZNYQJOEI-UHFFFAOYSA-N |
| SMILES | OC(=O)CCC(O)=O.CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1 |
| CAS Datenbank | 103628-48-4(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH318 (79.6%): Causes serious eye damage [Danger Serious eye damage/eye irritation]H361 (13%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H412 (16.7%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]P203, P264+P265, P273, P280, P305+P354+P338, P317, P318, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 54 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Regulatorische Informationen | Sumatriptan succinate: Does not have an individual approval but may be used under an appropriate group standard |
| Hazard Classes and Categories | Eye Dam. 1 (79.6%)Repr. 2 (13%)Aquatic Chronic 3 (16.7%) |
| Expositionspfade | Subcutaneous, Oral, Nasal, Transdermal |
| Toxizitätsübersicht | The 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Sumatriptan also blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve. |
| Signs and Symptoms | Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation. |
Anwendungen & Verwendung
Beschreibung
Sumatriptan succinate is a highly selective 5HT1-like receptor agonist introduced as a new treatment for migraine. It is indicated for the acute relief of migraine and cluster headache. Oral administration is reported to be free of substantial side effects. The compound appears to be a significant advance over the use of ergotamine and other agents in the treatment of migraine.
Verwenden
Sumatriptan Succinate is a selective 5-HT1B/1D-receptor agonist with anticonvulsant properties (1,2). Sumatriptan Succinate is used for migraine relief (2).